Friday 07 Apr/17 - a QCRI Frontiers in Cancer Research presentation by Dr. Jamie Fletcher
Frontiers of Cancer Research Presentation
Jamie Fletcher, PhD
Children's Cancer Institute Australia for Medical Research, Lowry Cancer Research Centre, University of New South Wales, Randwick NSW, Australia.
Friday, 07 April 2017 at 12:00 pm in QCRI Conference Rooms 100/01.
“Inhibition of MRP1 and precision medicine approaches in high risk neuroblastoma”
Multidrug resistance protein 1 (MRP1) is frequently overexpressed in tumours where it effluxes chemotherapeutic agents, protecting tumour cells from chemotherapy. MRP1 also effluxes glutathione (GSH), an antioxidant linked to tumour drug and radiotherapy resistance. We have developed highly selective MRP1 inhibitors with favourable pharmacological properties that block drug efflux whilst simultaneously enhancing MRP1-mediated GSH efflux. We are investigating the utility of these dual-function inhibitors for the treatment of MRP1-overexpressing cancers, in particular paediatric neuroblastoma, a tumour where high MRP1 expression is driven by amplification of the N-Myc oncogene. We are also currently undertaking a pilot study for a comprehensive precision medicine platform for children with high-risk cancer, including neuroblastoma. This platform incorporates targeted DNA sequencing, RNAseq, ex vivo drug sensitivity screening against a panel of 165 approved oncology drugs, and development of patient-derived xenograft (PDX) models for validation of the drugs/targets identified. This pilot demonstrates that a comprehensive approach is feasible and can substantially increase the ability to make personalized treatment recommendations.
Host: Dr. Susan P.C. Cole (email@example.com; x 32636)
Everyone is welcome!